Inside informationEnglish
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Cellectis
- Filed
- 09/06/2026, 22:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 114140_20260609